Harmony Biosciences Holdings, Inc. (HRMY) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Harmony Biosciences is a neuroscience company focused on rare neurological diseases, primarily commercializing WAKIX (pitolisant) for narcolepsy. The company operates a single reportable segment and has expanded its pipeline through acquisitions of Zynerba (ZYN002) and Epygenix (EPX-100), as well as new licensing agreements for next-generation pitolisant formulations and orexin receptor agonists.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Product Revenue | $200.5 million | $172.8 million | $385.2 million | $327.4 million |
| Gross Profit | $162.3 million | $140.7 million | $315.1 million | $267.8 million |
| Gross Margin | 81.0% | 81.4% | 81.8% | 81.8% |
| Operating Income | $48.2 million | $21.4 million | $104.4 million | $73.4 million |
| Net Income | $39.8 million | $11.6 million | $85.3 million | $49.9 million |
| Diluted EPS | $0.68 | $0.20 | $1.46 | $0.87 |
| Cash & Investments | $672.3 million (as of June 30, 2025) | |||
| Total Debt (Principal) | $173.8 million (as of June 30, 2025) | |||
| Operating Cash Flow (YTD) | $113.3 million | $73.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 16.0% QoQ and 17.7% YTD, driven by a 10.0% increase in units shipped and a 7% price increase implemented in January 2025, partially offset by higher rebates.
- Profitability Surge: Net income increased 242% for the quarter and 71% YTD. This was significantly aided by a reduction in non-deductible In-Process Research and Development (IPR&D) charges compared to the prior year.
- R&D Expenses: R&D expenses decreased 21.1% for the quarter and 1.3% YTD. The decrease is primarily due to the absence of $42.6 million in IPR&D charges recorded in Q2 2024 (related to the Bioprojet sublicense and Epygenix acquisition), partially offset by a new $15.0 million IPR&D charge in Q2 2025 for the CiRC Agreement.
- G&A Expenses: Increased 24.6% for the quarter, driven by a $6.1 million rise in legal and professional fees associated with patent litigation.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, and investments ($672.3 million) are sufficient to fund operations for the next 12 months.
- Pipeline Updates:
- WAKIX: FDA approved for pediatric narcolepsy (EDS) in June 2024; pediatric cataplexy sNDA resubmission planned for Q3 2025. Phase 3 TEMPO study for Prader-Willi Syndrome (PWS) initiated in Q1 2024.
- Next-Gen Pitolisant: Pitolisant GR pivotal bioequivalence study initiated Q1 2025 (data expected Q4 2025). Pitolisant HD Phase 3 trials planned for Q4 2025.
- ZYN002: Phase 3 RECONNECT study for Fragile X Syndrome enrollment complete; topline data expected Q3 2025.
- EPX-100: Two Phase 3 trials ongoing for Dravet Syndrome and Lennox-Gastaut Syndrome.
- Legal Proceedings (ANDA Litigation): The company has reached settlement agreements with Novugen, Annora, and Lupin regarding generic pitolisant. These settlements grant the generic manufacturers licenses to sell beginning in January 2030, or earlier under certain circumstances. Litigation with other parties (AET, Zenara, MSN) remains consolidated with a trial scheduled for February 2026.
- Recent Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted July 4, 2025, allows immediate expensing of domestic R&D. The company is evaluating the impact on financial statements.
Investor Verification Checklist
- Generic Competition Timeline: Verify the specific terms of the ANDA settlements (Novugen, Annora, Lupin) to confirm the January 2030 exclusivity expiration and any "earlier" trigger conditions.
- Rebate Impact: Monitor the trajectory of rebates and co-pay assistance, which offset the 7% price increase and could pressure gross margins if they accelerate.
- IPR&D Volatility: Note that R&D expenses are heavily influenced by one-time acquisition and licensing charges (e.g., the $15M CiRC charge); compare adjusted R&D to assess operational burn.
- Clinical Milestones: Track the Q3 2025 topline data for ZYN002 (Fragile X) and Q4 2025 data for Pitolisant GR, as these are critical value drivers.
- Debt Covenants: Confirm continued compliance with the Term Loan A covenants, specifically the senior secured net leverage ratio, given the company's debt load of $173.8 million.